The traditional treatments for lung cancer include surgical resection, radiotherapy and chemotherapy. In recent years, transbronchial artery intervention has become one of the important means for the treatment of middle and late stage lung cancer, and gradually becomes a routine work in the comprehensive treatment of lung cancer. Selective bronchial artery infusion chemotherapy has obvious advantages over systemic intravenous chemotherapy: the local drug concentration in tumor tissues is many times higher than that of systemic chemotherapy, and selective bronchial artery chemoembolization by using iodine oil-chemotherapy drug emulsion as embolic agent can enable iodine oil emulsion to selectively enter the tumor and occlude the tumor blood vessels, and can also enter the capillary bed of lung tissues to achieve the purpose of double embolization of bronchial artery and pulmonary artery. The iodine oil is slowly separated from the chemotherapeutic agent in the tumor, which results in high local drug concentration and long-lasting effect, and further improves the therapeutic effect. Lung cancer is mainly supplied by the bronchial artery. In addition to the tissue type of lung cancer, the type of blood supply of the tumor can also directly affect the efficacy of transbronchial artery intervention. For lung cancers with less blood supply, insensitive to chemotherapy, or large size, we mostly use percutaneous pulmonary puncture chemodissection or radioactive particle implantation, which can reduce tumor load and control complications in a short time. This has prolonged the survival time and improved the quality of life for many patients who lost the chance of surgery.